Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 11 February 2014 | By Alexander Gaffney, RAC,
Can a string of numbers or letters improve the European regulatory process?
EU regulators are hoping the answer is "yes," and have a plan to put that theory to the test.
In an 11 February 2014 announcement, the European Medicines Agency (EMA) said it is unveiling a new Unique Product Identifier (UPI) system that will apply a unique code to each new medicine the agency receives for review.
The tracking code will reportedly help the agency keep track of applications, improve the efficiency of its review processes, and "help create a unique platform for all pre-authorisation activities."
UPIs will be applied to all new medicines-not existing ones or ones already under review-at the agency, including any seeking orphan designation, scientific advice or pediatric development procedures.
Companies filing an application with EMA will need to submit a registration form to EMA with basic information on the medicine and send it to an EMA email account to receive a UPI.
The form calls for information on:
Thereafter, all interactions with the agency with respect to that medicine will need to reference that UPI.